Kornimate/medical-research-clean huggingface dataset:
mspt device usability study

Conditions: Multiple Sclerosis

Summary: the primary objective of this feasibility study is to evaluate the functionality (e.g., as defined by the primary endpoints) of the fully integrated multiple sclerosis performance test (mspt) device, when used by unsupervised participants with ms, or related conditions, with a broad range of disability, in multi-clinical-care environments. secondary objectives include: participant perception of usability of device; participant satisfaction with the device; ascertain the impact of different clinical environments on device usability; ascertain impact of assistive devices in usability of device; ascertain functionality of bluetooth remote as compared with manual timing.

this study does not involve evaluation(s) of the clinical efficacy of the mspt device or the efficacy of ms therapies. this feasibility study is examining the usability of the fully integrated mspt device. study participants will be enrolled for same-day testing.

Eligibility criteria:
key inclusion criteria: * diagnosis of ms, or related conditions, such as: clinically isolated syndrome (cis), neuromyelitis optica (nmo), and transverse myelitis (tm) * literacy of written english language as displayed on software tool * ability to understand and comprehend software tool from the audio and visual instructions provided in english key exclusion criteria: * study participants, who in the opinion of the investigator, have vision impairment that precludes their ability to see the ipad air2® screen/mspt device. * neurological illnesses/conditions, such as motor or vocal tics (including a diagnosis of tourette's syndrome), head trauma with significant loss of consciousness (\>30 minutes), cerebral palsy, dementia (including mild cognitive impairment and alzheimer's disease), chronic meningitis, parkinson's disease, and huntington's disease. note: other protocol defined inclusion/ exclusion criteria may apply.
proof of concept: "bottom's up" seat to treat constipation

Conditions: Constipation Aggravated; Pelvic Floor; Incompetency

Summary: supporting the pelvic floor can reduce symptoms of constipation in patients with refractory constipation due to pelvic floor laxity and excessive perineal descent by means of a modified toilet seat, known as "the bottom's up".

efficacy and safety of a unique pelvic floor support device that fits into the radiology defecography commode will be tested. patients with refractory constipation due to known pelvic floor laxity and/or excessive perineal descent will be examined without, then with the device in place. patients will complete questionnaires pertaining to device safety and efficacy before and after using the device. radiographic images to document efficacy of support plus adequate emptying will be acquired during the study resulting in very low dose radiation exposure.

Eligibility criteria:
10 males and female subjects greater that 18 years of age with aggravated constipation due to pelvic floor laxity of at least 4 cm and excessive perineal descent of at least 4 cm will be evaluated. patients with constipation but no excessive laxity or descent will not be evaluated. patients must be willing to sign consent, undergo defecography with and without "the bottom's up" device.
peer-to-peer support program in improving quality of life outcomes in patients with gynecologic cancer and their caregivers

Conditions: Cervical Carcinoma; Ovarian Carcinoma; Uterine Corpus Cancer; Vaginal Carcinoma; Vulvar Carcinoma

Summary: this pilot clinical trial studies a peer-to-peer support program in improving quality of life outcomes in patients with gynecologic cancer and their caregivers. peer-to-peer support and mentoring may help improve quality of life and reduce symptoms of distress in gynecologic cancer patients and their families.

primary objectives: i. to test the feasibility and acceptability of a woman-to-woman (w2w) program for patients with gynecologic cancer at city of hope (coh). address the following descriptive research questions: were patients, mentors, and patients' family caregivers satisfied with the timing, format, and content of the program? did the program benefit patients, mentors, and patients' family caregivers? outline: patients participate in the w2w program for which they are matched with a trained mentor and followed throughout treatment by phone, email, and/or in person. after completion of study, patients are followed up at 6 and 12 months.

Eligibility criteria:
inclusion criteria: * patient participants * patients with newly diagnosed or recurrent gynecologic cancer (ovarian, uterine, cervical, vaginal, vulvar) actively undergoing treatment (chemotherapy, surgery, or radiation therapy) at coh (including duarte and south pasadena campuses) * english-speaking patients * peer mentors * peer mentors will be past gynecologic cancer patients not currently undergoing treatment for their cancer, and considered without evidence of disease * over age 18 * peer mentors: english-speaking patients * this study is open to patients of all races and ethnicities exclusion criteria: * peer mentors: * major psychiatric disease * currently undergoing treatment for active gynecologic cancer
reliability and validity study of the turkish version of the parkinson's disease dyskinesia scale (pdys-26)

Conditions: Idiopathic Parkinson Disease; Dyskinesias; Quality of Life

Summary: the aim of this methodological study was to investigate the turkish validity and reliability of the parkinson's disease dyskinesia scale (pdys-26).the scale evaluates choreic dyskinesia.measures the impact of dyskinesia on activities of daily living in patients with parkinson's disease. hypotheses of the study: * parkinson's disease dyskinesia scale (pdys-26) is reliable in turkish. * parkinson's disease dyskinesia scale (pdys-26) is valid in turkish. to determine the validity of dyskinesia; * tampa kinesiophobia scale, * mini bestest, * activity specific balance safety scale (abc) and * parkinson's disease questionnaire-39 will be evaluated.

in parkinson's disease, a neurodegenerative disorder affecting the peripheral and central nervous system, dyskinesia is a common symptom that occurs as disease processes progress and leads to disability. the term dyskinesia is a general term that covers many movement disorders. in general, it can be defined as mild to severe abnormal and involuntary muscle movements. in individuals with parkinson's disease, it is a natural consequence of the neurodegenerative process and a motor complication of the gold standard l-dopa. assessment of dyskinesia in parkinson's patients is important for the implementation of appropriate medical, surgical and rehabilitation protocols. there are few scales and patient diaries that clinically assess the effect of interventions for dyskinesia. at the same time, there are deficiencies related to the reliability and validity studies of these existing scales in different languages. therefore, limitations may arise in the assessment of dyskinesia. for this purpose, our study aims to investigate the reliability and validity of the parkinson's disease dyskinesia scale (pdys-26) in turkish in patients diagnosed with 130 idiopathic parkinson's patients.in the study, the parkinson's disease dyskinesia scale (pdys-26) will be translated into turkish with the "back translation" method and will be finalized after the approval of the commission consisting of relevant health professionals. the final version of the scale will be applied to parkinson's patients. to determine the validity of dyskinesia; tampa kinesiophobia scale, mini bestest activity specific balance safety scale (abc) and parkinson's disease questionnaire-39 will be evaluated.

Eligibility criteria:
inclusion criteria: * being diagnosed with idiopathic parkinson's disease * h\&y stage 1-3 * updrs dyskinesia item score ≥1 * accepting to participate in the study exclusion criteria: * diagnosis of atypical-secondary parkinsonism * severe musculoskeletal, neurological and/or cardiopulmonary problems that may affect the results of the assessment * mini mental state examination score \< 24

Keywords: parkinson's disease dyskinesia parkinson's disease dyskinesia scale
effects of simeox on airway clearance in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: this study will investigate the contribution of simeox technology on the effectiveness of bronchial drainage. this is a crossover study to evaluate the contribution of simeox on the effectiveness of bronchial drainage (verified by the amount of sputum secretions, the rheology of sputum secretions and the subjective sensation of ease of sputum) in patients with cystic fibrosis. patients will perform, in randomized order (1) a 30-min session of autogenic drainage, (2) a 30-min session of autogenic drainage with the simeox device. sputum will be collected during and after the session. the two sessions will be performed with minimum washout time of 24 hours.


Eligibility criteria:
inclusion criteria: * adults with cystic fibrosis * chronic bronchorrhea, able to expectorate by themselves * hospitalized exclusion criteria: * regular use of simeox, * difficulties in understanding instructions, * severe cardiac comorbidity.
exparel vs block for acl reconstruction

Conditions: ACL; Postoperative Pain

Summary: liposomal bupivacaine or exparel (pacira biosciences) is a long-lasting nonopioid analgesic that was initially utilized as an infiltrative agent but has more recently become u.s. food and drug administration (fda) approved for use in interscalene brachial plexus nerve blockade as well as infiltrative blockade. delivery in this form is reported to provide up to 72 hours of extended-release bupivacaine. exparel's use as a regional anesthetic has also become increasingly common and has shown promise when utilized in anterior cruciate ligament (acl) reconstruction.


Eligibility criteria:
inclusion criteria: * paticipants with acl rupture amenable to reconstruction with btb autograft identified in clinic by one of 4 different surgeons * primary acl reconstruction with autograft +/- partial meniscectomy +/- lateral extra-articular tenodesis * age 18 and older * english speaking * ability to complete surveys by phone or in person * ability to provide informed consent exclusion criteria: * revision cases * multi-ligamentous knee injuries * cartilage or meniscal procedures that prevent adherence to immediate weight bearing and range of motion rehab protocol * acl reconstruction utilizing non-bone-patellar tendon-bone autografts * allergies to study medications * non-english speakers * known alcohol or narcotic abuse history * existing contract with a pain specialist due to underlying preoperative pain syndrome * preoperative opioid use within the 3 months prior to surgery
a study of rizatriptan co-administered with acetaminophen for the treatment of acute migraine

Conditions: Migraine

Summary: the purpose of this study is to test an experimental drug combination of two medications currently approved by the food and drug administration (fda) for migraine headache or other pain. these are called rizatriptan given with acetaminophen.


Eligibility criteria:
inclusion criteria: * subject is at least 18 years of age * subject has at least a 6 month history of migraine, with or without aura * subject can distinguish between migraine attacks and other types of headaches * subject of childbearing potential agrees to use adequate contraception exclusion criteria: * subject typically has fewer than 1 or greater than 6 migraine attacks per month * subject typically has greater than 10 headache days per month * subject has evidence of ischemic heart disease * subject has uncontrolled high blood pressure * subject has a history, within 1 year, or current evidence of drug or alcohol abuse \*this list is not all inclusive\*
fermented iron-rich supplement in reducing anemia

Conditions: Iron Deficiency Anemia

Summary: the consequences of iron deficiency anemia in women are enormous, and especially in developing countries, as the condition adversely affects both their productive and reproductive capabilities. the study seeks to: 1) compare changes in iron status indicators among women receiving an iron-rich organic food supplement versus ferrous sulfate supplement, and 2) determine the suitable level of food supplement needed to prevent/reduce iron deficiency anemia among women in developing country settings. a double-blind, randomized, controlled, intervention trial will be implemented in women of childbearing age, 60 women with iron deficiency anemia and 60 women with iron deficiency. after screening potential subjects (up to 500 expected), approximately 30 will be recruited into each of four study groups; assuming 30% dropout rate, to detect an increase of 30% in ferritin as significant between the two time points at 80% power and alpha value of 0.05. subjects who meet the inclusion criteria will be randomized into the four groups consisting of: 2 control groups (daily 60mg ferrous sulfate (fs-60) or daily 10mg ferrous sulfate (fs-10)), and 2 test groups (daily 60mg iron-rich supplement (irs-60) or 10mg iron-rich supplement (irs-10)). subjects will take daily fs-60 and irs-60 under supervision for 8 weeks while subjects taking fs-10 and irs-10 will take the supplement under supervision for 12 consecutive weeks.

the design will involve screening of about 500 female adult students and staff of the university of ghana who meet initial the inclusion criteria. screening will involve pregnancy testing, assessment of hemoglobin, and ferritin and also administration of a health history questionnaire. thereafter, 120 eligible subjects will enrolled and randomized to recieve the treatment. all subjects will complete 3-day dietary record (including 2 weekdays and 1 weekend) at baseline and at endline (i.e. one week prior to treatment completion). the dietary data will be analyzed using nationally-generated food composition tables together with the esha food processor software. in addition, body weight and height will be measured using standard methods at baseline and end of the study. weekly monitoring of side effects will be recorded. fasting blood samples will be collected at baseline and endline to enable determination of anemia status and other indicators including serum ferritin, transferrin receptor and full blood count, together with c-reactive protein.

Eligibility criteria:
inclusion criteria: * 18-49 years * regular menstruation in the last three months * hemoglobin \<12 mg/dl; * serum ferittin\<20mcg/l * bmi 18.5kg/m\^2 to 29.9 kg/m\^2 exclusion criteria: * history of gastrointestinal or hematological disorders, * taking medications that could interfere with hematopoiesis or dietary iron absorption * pregnant (based on pregnancy test).
synthetic cranioplasty peek versus uhmwp

Conditions: Cranium; Deformity

Summary: the purpose of this study is to report the investigators experience with synthetic reconstruction of cranial defects using computer guided milled uhmwp, in terms of benefits and limitations both clinically and radiographically in comparison to peek implants.

statement of the problem: to this date, there is still no consensus on the ideal material for cranial reconstruction. research journey involved the use of autologous grafts, allografts, xenografts, and a wide array of synthetic materials for cranioplasty. the autologous bone flap, although associated with less infection than allo or xenografts, is not always a possibility after comminution or osteomyelitis and still has the common drawbacks of storage, aseptic bone flap necrosis (abfr) and the need for a second surgery. titanium offers lower cost but is quite difficult to shape, radiopaque and exhibits high dehiscence with thin skin biotypes. polyetheretherketone (peek) has been gaining popularity during the recent years for lower rates of graft failure, however, it still holds a risk of postoperative inflammatory complications, is of exceedingly high cost most studies utilizing it are retrospective and observational. rationale for conducting the research: cranioplasty procedures carry functional and esthetic challenges and the most suitable graft to be used remains controversial. uhmwp use in biomedical applications is greatly due to its outstanding mechanical properties and biocompatibility which, when coupled with three d computer guided milling technology to reconstruct complex and large cranial defects, can provide durable patient specific implants (psi). however, no interventional studies exist in the literature on its application in cranioplasty. explanation for choice of comparators: peek as a semicrystalline thermoplastic polymer has a thickness and elasticity comparable to cortical bone making it one of the most commonly used bone substitute materials and is currently recommended as a standard viable option for cranial defects.

Eligibility criteria:
inclusion criteria: * cranial defect patients * patients eligible for simultaneous craniectomy and cranioplasty. * asa i \& ii exclusion criteria: * active infection. * medically compromised patients (asa ≥3). * hydrocephalus/brain swelling
cuhk jockey club hope 4 care programme - fes bike

Conditions: Stroke

Summary: the hong kong jockey club charities trust has supported cuhk to launch a three-year project 'cuhk jockey club hope4care programme' to implement four evidence-based advanced rehabilitation technologies in 40 local elderly day care centres and rehabilitation centres, to benefit the community. our research team had developed the "interactive fes cycling system" that can be used as tools for rehabilitation by individuals who have suffered from a stroke or elderly. the system can integrate both motor power and muscle power in order to facilitate an active rehabilitative exercise.


Eligibility criteria:
inclusion criteria: * diagnosis of ischemic brain injury or intracerebral haemorrhage shown by magnetic resonance imaging or computed tomography after the onset of stroke; * significant gait deficit (functional ambulatory category, fac\<4 \[person cannot walk independently\]). exclusion criteria: * any additional medical or psychological condition that would affect their ability to comply with the study protocol, e.g., a significant orthopaedic or chronic pain condition, major post-stroke depression, epilepsy, artificial cardiac pacemaker / joint; * severe hip, knee or ankle contracture that would preclude passive range of motion of the leg (mas\<3).
vitreous surgery with intraocular assistance

Conditions: Traction Retinal Detachments; Rhegmatogenous Retinal Detachments; Dislocated Intraocular Lens

Summary: to assess the safety of vitreous surgery with intraocular assistance (visia) \& to identify and document with video evidence and surgeon's case report forms intraocular maneuvers that are facilitated by visia.

standard care surgery will be done with a few novel additions to facilitate the surgical procedure. currently 3 ports are inserted by creating holes in the sclera (white part of the eye) to enter into the posterior part of the eye. when complex dissection is needed, a fourth port will be inserted. the assistant will insert light source through the 4th port. this eliminates the need for the surgeon to hold the light in one hand. hence allows freeing of both hands for the surgeon to use a forceps in one hand to grasp and elevate membranes and a scissors in the other to cut connections between the retina and the membranes. when membranes are particularly thick, it can be difficult to dissect with a single forceps holding up the membrane. in this situation, a 5th port will be inserted allowing the assistant to insert a light source through one and a forceps though another. the surgeon will have a forceps in one hand and a scissors in another making dissection process more efficient.

Eligibility criteria:
inclusion criteria: all subjects must meet the following criteria to be eligible for study entry: * signed informed consent and authorization of use and disclosure of protected health information * age ≥18 years * subject will have complex retinal pathology for which it is judged that surgical objectives could be facilitated by visia exclusion criteria: subjects who meet any of the following criteria will be ineligible for study entry: • patients with disease processes such as macular pucker and macular hole that are generally well-managed by standard two-handed vitrectomy.
amniotic membrane in decompressive craniectomy to reduce scarring

Conditions: Scarring

Summary: the purpose of this study is to evaluate the effectiveness of dhacm in reducing scar tissue formation in craniectomy patients as well as facilitating reoperation and repair. specifically this study compares craniectomy without dhacm application to craniectomy with placement of dhacm between the galea and dura over dural suture line and/or exposed parenchyma.


Eligibility criteria:
inclusion criteria: * adults ages 18 or older. * diagnosed with closed head trauma or cerebral infarction where decompressive craniectomy with durotomy is performed. * willingness to comply with study procedures. * the patient's or legally authorized representative's (lar's) ability to give full written consent. exclusion criteria: * prior surgery at the site * participation in another ongoing trial * open cranial wounds * site exhibits clinical signs and symptoms of local infection. * current diagnosis of cancer at the site * prior radiation therapy treatment at the site. * patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening. * known history of having acquired immunodeficiency syndrome (aids) or hiv. * presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment. * currently taking medications which could affect graft incorporation (supervising physician's discretion). * allergy to gentamicin sulfate and/or streptomycin sulfate
clinical trial of hyperbaric oxygen treatment in trigeminal neuralgia patients

Conditions: Trigeminal Neuralgia; Pain

Summary: the purpose of this study is to determine whether the hyperbaric oxygen treatment reduces pain and improve the life quality in trigeminal neuralgia patients.

trigeminal neuralgia(tn) is a recurrent severe shooting neuropathic pain. treatment of this pain continues to be a challenge in clinical pain management. hyperbaric oxygen (hbo) has been used of neuropathic diseases, which can improve blood partial pressure of oxygen, reduce edema, relieve neural oppression and attenuate inflammatory response. the hypothesis of this protocol is that hyperbaric oxygen treatment could relieve neuropathic pain and improve the quality of life in tn patients. visual analogue scale (vas) and the mcgill pain questionnaire (mgpq) will be assessed before the initiation of the study, after hyperbaric oxygen (hbo) treatment and at monthly intervals for the subsequent 3 months. titration of dosage and pain frequency will be recorded throughout the study. clinical global impression (cgi) by the individual patient will be evaluated at monthly intervals after hbo treatment.

Eligibility criteria:
inclusion criteria: 1. age 18-70 2. primary tn patient (mri examination support diagnosis) 3. suffering from this pain for at least 3 months 4. vas﹥40mm 5. patient can assess pain intensity correctly exclusion criteria: 1. undergone surgery for tn(including nerve injections) within the last year 2. oral medicine change within the last week 3. with other diseases of nervous system

Keywords: trigeminal neuralgia pain hbo vas mgpq